Pipeline

Our RAMP™ drug innovation engine facilitates the development of more selective Abl inhibitors with greater potency and safety than commercially marketed Abl kinase inhibitors used as anti-cancer agents. The c-Abl inhibitors that have emerged from our development can be administered chronically and systemically.